Aridis Pharmaceuticals 2023 Investor Presentation Respiratory Health

Late-stage biopharmaceutical company developing innovative therapeutics for respiratory and infectious diseases. The presentation highlights Phase 3 asset AR-301 for acute pneumonia treatment with ~$1B market opportunity and Phase 2 asset AR-501 for cystic fibrosis, supported by strong clinical data.